Litigation Details for Grunenthal GmbH v. Alkem Laboratories Limited (Fed. Cir. 2017)

Grunenthal GmbH v. Alkem Laboratories Limited (Fed. Cir. 2017)

Docket		Date Filed	2017-05-18
Court	Court of Appeals for the Federal Circuit	Date Terminated	2019-03-28
Cause		Assigned To
Jury Demand		Referred To
Patents	8,536,130
Link to Docket	External link to docket

Details for Grunenthal GmbH v. Alkem Laboratories Limited (Fed. Cir. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-05-18				External link to document

Grunenthal GmbH v. Alkem Laboratories Limited, 17-2048: Patent Litigation Summary and Analysis

Last updated: October 29, 2026

Grunenthal GmbH v. Alkem Laboratories Limited, Federal Circuit docket No. 17-2048, concerned Alkem's abbreviated new drug application for a generic version of Grunenthal's tapentadol extended-release product, Nucynta ER. The dispute centered on U.S. Patent No. 8,337,888, which covered extended-release tapentadol formulations. The Federal Circuit affirmed the district court's judgment in favor of Grunenthal, leaving the asserted patent claims enforceable against Alkem's ANDA product. Grunenthal GmbH v. Alkem Laboratories Ltd., 919 F.3d 1333 (Fed. Cir. 2019).

What drug and patent were at issue in Grunenthal v. Alkem?

The case involved tapentadol hydrochloride, an opioid analgesic with norepinephrine reuptake-inhibition activity. Grunenthal developed and commercialized Nucynta and Nucynta ER in the United States. Alkem sought FDA approval to market a generic extended-release tapentadol product.

Item	Details
Branded drug	Nucynta ER
Active ingredient	Tapentadol hydrochloride
Dosage form	Extended-release oral tablets
NDA holder and innovator	Janssen Pharmaceuticals, Inc., with Grunenthal as patent owner or litigation party
Generic applicant	Alkem Laboratories Limited
Regulatory pathway	ANDA under the Hatch-Waxman Act
Federal Circuit docket	17-2048
Principal patent	U.S. Patent No. 8,337,888
Federal Circuit citation	919 F.3d 1333
Decision date	March 14, 2019

The asserted patent covered pharmaceutical compositions designed to deliver tapentadol over an extended period. The formulation technology was relevant because immediate-release and extended-release tapentadol products have materially different dosing profiles, abuse-related considerations and clinical-use characteristics.

What did the district court decide?

Grunenthal sued Alkem after receiving an ANDA notice containing a Paragraph IV certification. The certification asserted that the relevant patent was invalid, unenforceable or would not be infringed by Alkem's proposed generic product.

The district court held that Alkem's ANDA product infringed the asserted claims of the '888 patent and rejected Alkem's invalidity defenses. The decision preserved the patent barrier against FDA approval and commercial launch of the accused product during the relevant statutory period.

The case involved a bench trial rather than a jury trial. The district court evaluated infringement and obviousness based on the patent claims, the formulation prior art, expert testimony and the technical characteristics of Alkem's proposed product.

How did the Federal Circuit rule in Grunenthal v. Alkem?

The Federal Circuit affirmed the district court's judgment. The appellate court upheld the conclusions that:

1. Alkem's ANDA product fell within the scope of the asserted claims.
2. Alkem did not establish that the claims were invalid for obviousness.
3. The evidence supported the district court's findings regarding the claimed extended-release formulation and the relevant prior art.

The decision illustrates the Federal Circuit's treatment of pharmaceutical formulation patents where the prior art discloses the active ingredient but does not establish that the claimed release profile, excipient system or formulation architecture would have been obvious to a skilled formulator.

The court distinguished between knowing that tapentadol could be used therapeutically and knowing how to formulate it into the specific extended-release system claimed by the patent. Disclosure of the active pharmaceutical ingredient alone did not resolve the formulation question.

Why was the patent not obvious?

The principal invalidity dispute concerned whether the prior art provided a sufficient reason to select and combine the relevant formulation features with a reasonable expectation of success.

For pharmaceutical formulation claims, an obviousness analysis generally considers:

• The identity and scope of the prior-art references.
• The properties of tapentadol relevant to extended-release delivery.
• The selection of excipients and matrix components.
• The target dissolution or release profile.
• The predictability of the formulation process.
• Evidence of unexpected results.
• Commercial success and other objective indicia, when adequately tied to the claimed invention.

The Federal Circuit's decision preserved the district court's conclusion that Alkem had not carried its burden. The court did not treat the existence of a known active ingredient or a general desire to create an extended-release dosage form as sufficient to invalidate the specific formulation claims.

That distinction is important for generic-drug litigation. A formulation patent can remain enforceable even where the underlying molecule is old, the therapeutic indication is known and the general concept of extended release is conventional. The patent's strength depends on the technical limitations actually recited in the claims and the evidence connecting those limitations to the commercial product.

What was the Paragraph IV challenge?

Alkem's ANDA challenge was based on a Paragraph IV certification. That certification alleged that the listed patent was invalid, unenforceable or not infringed.

Grunenthal's infringement action triggered the Hatch-Waxman litigation framework. The filing of the patent suit generally imposed a 30-month stay on FDA approval of the ANDA, subject to statutory exceptions and court orders. The litigation therefore had both a patent-validity function and a regulatory-timing function.

The Federal Circuit's affirmance reduced the immediate risk that Alkem could obtain approval and launch its generic extended-release tapentadol product based on the challenged ANDA.

What was the impact on generic entry?

The decision delayed or constrained Alkem's ability to launch the accused product until the patent barrier expired, was judicially removed or was otherwise resolved through a separate agreement.

The commercial effect depended on several factors:

Generic-entry factor	Effect in this case
Patent validity	Federal Circuit affirmance preserved the asserted patent
Infringement	Alkem's proposed product was found to infringe
FDA approval	Approval was subject to the Hatch-Waxman litigation stay and patent outcome
Launch timing	Controlled by patent expiration, court orders and any settlement terms
At-risk launch	Increased exposure because the asserted patent had been upheld
Substitution	Dependent on FDA approval, state substitution rules and product availability
Price erosion	Potentially delayed for the covered extended-release product

An at-risk launch would have exposed Alkem to damages and injunctive remedies if the patent remained enforceable. The appellate affirmance increased the downside of launching before final patent expiry.

What FDA and Orange Book issues are relevant?

Nucynta ER was approved by the FDA as an extended-release tapentadol product. The relevant regulatory dispute was tied to an ANDA rather than a biosimilar application or a biologics license application.

The case did not involve:

• A biologic or biosimilar product.
• An interchangeability determination.
• Patent dance procedures under the Biologics Price Competition and Innovation Act.
• A 351(k) application.
• A product-specific biologic exclusivity period.

The relevant FDA mechanisms were the NDA, Orange Book patent listing, Paragraph IV certification and the 30-month stay under the Hatch-Waxman framework. The patent listing gave Grunenthal the basis to bring the infringement action after receiving Alkem's certification.

Orange Book status should be evaluated by patent number and approved product listing. The litigation itself established the enforceability of the asserted patent against Alkem's ANDA product; it did not establish the status of every patent that may have been listed for Nucynta or Nucynta ER.

Did the case involve a method-of-use patent?

The reported Federal Circuit dispute principally concerned formulation protection for extended-release tapentadol. It was not principally a dispute over a narrow method-of-use claim, such as treating a particular patient subgroup or administering tapentadol for a specific secondary indication.

The distinction matters because method-of-use patents are often addressed through a Section viii statement, while formulation patents generally require a Paragraph IV certification if the generic product is alleged to infringe. A formulation patent can therefore create a broader regulatory obstacle than a use patent that the applicant can carve out of its labeling.

What formulation technology was protected?

The asserted patent protected an extended-release pharmaceutical composition containing tapentadol. The commercial value of this type of patent arises from the relationship between the drug substance and the delivery system.

Relevant technical variables include:

• Release rate over the dosing interval.
• Matrix-forming materials.
• Excipient selection.
• Tablet composition.
• Drug loading.
• Dissolution behavior.
• Dose uniformity.
• Manufacturing conditions.
• Stability and storage performance.

The patent did not merely claim tapentadol as a chemical compound. Its protection was directed to how tapentadol was formulated and released. That distinction limited the scope of the holding but also supported patentability against prior art that disclosed tapentadol without the claimed formulation combination.

How strong was Grunenthal's patent estate?

The litigation outcome indicates strong enforcement value for the asserted '888 patent against the Alkem ANDA product. The Federal Circuit affirmance provided several advantages:

1. The patent survived a validity challenge.
2. Infringement findings were preserved.
3. The patent remained relevant to FDA approval timing.
4. Alkem faced greater risk from an at-risk launch.
5. The decision strengthened Grunenthal's negotiating position in generic-entry discussions.

The decision did not establish that every patent covering Nucynta ER would survive challenge. Patent strength must be assessed claim by claim and patent by patent. Formulation patents may have meaningful commercial leverage even when compound patents have expired, provided the claims cover the proposed generic product and withstand invalidity challenges.

Were settlement agreements or licensing deals disclosed?

The Federal Circuit decision did not establish a settlement agreement or license between Grunenthal and Alkem. A judicial opinion should not be treated as evidence of a commercial settlement unless the settlement is separately reported in court filings, an FTC review, an SEC filing or another authoritative source.

The appellate opinion addressed the merits of the patent dispute. It did not create a license for Alkem, authorize an early launch or establish a royalty arrangement.

What litigation risks did Alkem face after the appeal?

After the affirmance, Alkem faced the following risks:

• Continued inability to launch the accused product before the relevant patent barrier ended.
• Potential damages for an unauthorized commercial launch.
• Injunctive relief.
• Loss of first-launch economics.
• Additional litigation expense.
• Reduced negotiating leverage in any later settlement.
• Potential redesign costs if a noninfringing formulation could be developed.

A generic applicant can reduce these risks through a revised formulation, a noninfringement position based on a modified ANDA product, a covenant not to sue, a settlement with an agreed launch date or a later validity challenge based on new evidence. The Grunenthal decision made the original Alkem formulation materially more difficult to commercialize.

How does Grunenthal v. Alkem compare with ordinary generic patent cases?

The case is significant because the branded product's market protection depended on formulation claims rather than only on the active ingredient.

Issue	Grunenthal v. Alkem	Typical compound-patent case
Protected subject matter	Extended-release formulation	Active chemical compound
Core technical dispute	Release system and formulation limitations	Compound structure and chemical scope
Prior-art question	Whether formulation features were predictable	Whether the molecule was disclosed or obvious
Generic design-around	Reformulate dosage form or release system	Usually difficult if compound claim survives
Regulatory impact	ANDA patent certification and stay	Same Hatch-Waxman framework
Biosimilar relevance	None	None unless the product is biologic

The case is useful precedent for branded companies assessing whether a formulation patent can support a Paragraph IV action after broader compound protection has weakened.

Key Takeaways

• Grunenthal GmbH v. Alkem Laboratories involved generic extended-release tapentadol and U.S. Patent No. 8,337,888.
• The Federal Circuit affirmed the district court's judgment for Grunenthal.
• Alkem's ANDA product was found to infringe the asserted formulation claims.
• The patent survived Alkem's obviousness challenge.
• The decision preserved the patent obstacle to Alkem's proposed generic launch.
• The case involved Hatch-Waxman litigation, a Paragraph IV certification and Orange Book-listed patent protection.
• It did not involve biosimilars, biologic exclusivity or a BPCIA patent dispute.
• The ruling demonstrates the commercial value of formulation patents covering extended-release delivery systems.

FAQs

What was U.S. Patent No. 8,337,888 used to protect?

The patent protected an extended-release pharmaceutical composition containing tapentadol, including formulation limitations relevant to controlled drug release.

Did Alkem win its appeal in Grunenthal v. Alkem?

No. The Federal Circuit affirmed the district court's judgment favoring Grunenthal.

Was Nucynta ER's active ingredient still under a compound patent?

The Federal Circuit case focused on formulation protection rather than resolving the entire patent estate for tapentadol. Compound, formulation and method-of-use patents must be analyzed separately.

Did the decision authorize Alkem to launch its generic?

No. The affirmance preserved the adverse infringement and validity findings against Alkem's ANDA product.

Is Grunenthal v. Alkem relevant to abuse-deterrent opioid patent strategy?

Yes. The decision is relevant to companies evaluating controlled-release opioid formulations, particularly where patent claims distinguish the product through release behavior, matrix composition or formulation architecture.

References

1. Grunenthal GmbH v. Alkem Laboratories Ltd., 919 F.3d 1333 (Fed. Cir. 2019).

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.

3. U.S. Food and Drug Administration. (n.d.). Hatch-Waxman amendments and abbreviated new drug applications. FDA.

4. U.S. Patent No. 8,337,888. (2012). United States Patent and Trademark Office.